Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
500.19
-0.96 (-0.19%)
At close: May 5, 2025, 4:00 PM
485.00
-15.19 (-3.04%)
After-hours: May 5, 2025, 4:35 PM EDT
Vertex Pharmaceuticals Revenue
Vertex Pharmaceuticals had revenue of $2.77B in the quarter ending March 31, 2025, with 2.96% growth. This brings the company's revenue in the last twelve months to $11.10B, up 8.98% year-over-year. In the year 2024, Vertex Pharmaceuticals had annual revenue of $11.02B with 11.66% growth.
Revenue (ttm)
$11.10B
Revenue Growth
+8.98%
P/S Ratio
11.61
Revenue / Employee
n/a
Employees
n/a
Market Cap
128.59B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 11.02B | 1.15B | 11.66% |
Dec 31, 2023 | 9.87B | 938.50M | 10.51% |
Dec 31, 2022 | 8.93B | 1.36B | 17.91% |
Dec 31, 2021 | 7.57B | 1.37B | 22.06% |
Dec 31, 2020 | 6.21B | 2.04B | 49.08% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Thermo Fisher Scientific | 42.90B |
VRTX News
- 6 hours ago - Vertex Pharmaceuticals Incorporated (VRTX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 9 hours ago - Vertex misses quarterly results on weaker-than-expected demand for cystic fibrosis drug - Reuters
- 10 hours ago - Vertex Reports First Quarter 2025 Financial Results - Business Wire
- 11 hours ago - Vertex Has Lost Some Sizzle Into Q1 Earnings - Can Alyftrek, Journavx Reignite The Momentum? - Benzinga
- 15 hours ago - Vertex Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Benzinga
- 6 days ago - Baron Health Care Fund Q1 2025 Top Net Purchases And Sales - Seeking Alpha
- 6 days ago - Baron Health Care Fund Q1 2025 Top Contributors And Detractors - Seeking Alpha
- 13 days ago - Eli Lilly, Vertex, AbbVie and More Pharma Stocks to Own as Tariffs Loom - Barrons